CVS · News · 20260806N

PBM Regulatory Risk

CVS HEALTH Corp · 2026-08-06 · Importance 39 · Surprise 42

Third-party reporting identified continuing regulatory uncertainty for CVS’s Caremark pharmacy-benefit-management business. Coverage highlighted potential 2027 pressure from changes to the 340B pharmacy program and declining Caremark membership. Moody’s revised CVS’s ratings outlook from stable to positive while affirming its Baa3 senior unsecured rating, but continued to cite regulatory uncertainty in the PBM business. The digest did not identify a finalized statute, rule, jurisdiction-specific enforcement action or quantified financial impact.

Key facts

• CVS flagged 2027 pressure from 340B changes and Caremark membership declines on its earnings call. source